The epidermal growth factor receptor: a new target for anticancer therapy.
Grünwald
Viktor
V
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hidalgo
Manuel
M
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009025:Morpholines; D011799:Quinazolines; C420268:Canertinib; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib